Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 17 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

OTI1H1-Defined MAGEA3-Directed Immunoreactivity and Survival in Pancreatic Ductal Adenocarcinoma: A Single-Center Study

  • Goran Glavčić1,2
  • Marin Glavčić3
  • Suzana Janković1,4
  • Dubravka Mužina1,2
  • Zdenko Bilić1
  • Nina Blažević5
  • Zvonimir Misir1,4
  • Jasmina Hranjec1,4
  • Andro Košec6,7
  • Petra Radulović4,8
8 affiliations
  1. 1Clinic for Surgery, University Hospital Centre “Sestre milosrdnice”, 10000 Zagreb, Croatia
  2. 2School of Medicine, Catholic University of Croatia, 10000 Zagreb, Croatia
  3. 3Clinic for Orthopedics and Traumatology, University Hospital Dubrava, 10000 Zagreb, Croatia
  4. 4School of Dental Medicine, University of Zagreb, 10000 Zagreb, Croatia
  5. 5Clinic for Internal Medicine, University Hospital Centre “Sestre milosrdnice”, 10000 Zagreb, Croatia
  6. 6Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Centre “Sestre milosrdnice”, 10000 Zagreb, Croatia
  7. 7School of Medicine, University of Zagreb, 10000 Zagreb, Croatia
  8. 8Clinical Department of Pathology and Cytology “Ljudevit Jurak”, University Hospital Centre “Sestre milosrdnice”, 10000 Zagreb, Croatia
Open at sourceDOICite

Abstract

Background/Objectives: Melanoma-associated antigen A3 (MAGEA3) is a cancer–testis antigen with potential biological and prognostic relevance in pancreatic ductal adenocarcinoma (PDAC). This study evaluated the association between OTI1H1-defined MAGEA3-directed immunoreactivity and clinicopathological characteristics and overall survival after pancreatic resection for PDAC. Methods: This retrospective cohort included 76 patients with histologically confirmed PDAC. Patients who died within 30 postoperative days were excluded, and all tumors were retrospectively restaged according to the eighth edition of the AJCC TNM classification. Immunohistochemical staining was assessed using the mouse monoclonal anti-MAGE3 antibody clone OTI1H1 (ab140678, Abcam) by a single experienced pathologist blinded to clinical and outcome data. The percentage of immunoreactive tumor cells was retained as the principal exploratory quantitative measure; the prespecified <10% versus ≥10% classification was evaluated secondarily. Results: Thirty-six of 76 tumors (47.4%) had ≥10% OTI1H1-reactive tumor cells. When staining was modeled continuously, the adjusted HR per 10-percentage-point increase was 0.969 (95% CI 0.898–1.046; p = 0.420). For the secondary binary classification, the adjusted HR for ≥10% versus <10% staining was 0.745 (95% CI 0.417–1.331; p = 0.320). No statistically clear association with overall survival was observed; however, the confidence intervals do not exclude potentially clinically relevant associations in either direction. Conclusions: No statistically clear association between OTI1H1-defined immunoreactivity and overall survival was observed in this cohort. Because OTI1H1 has known cross-reactivity with selected MAGE-A family proteins and no orthogonal molecular validation was performed, these findings should be interpreted as assay-specific and do not establish biological inactivity of MAGEA3 or related MAGE-A proteins.

Related

  1. Skeletal Muscle Index, Tumor and Systemic Immunity, and Survival in Advanced Pancreatic Ductal Adenocarcinoma
    Yue Ma, Ru Jia, Mengjiao Fan +12
    Cancer medicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  2. Clonogenic survival and relative biological effectiveness of pancreatic ductal adenocarcinoma under pristine and spread-out Bragg peak irradiation with protons and carbon ions.
    J. M. Denbeigh, A. Kneringer, W. E. Radstake +10
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  3. KRAS-driven metabolic reprogramming of enhanced MFSD2A-mediated lysophosphatidylcholine scavenging promotes survival and progression of pancreatic ductal adenocarcinoma
    y. chen, C. Haffner, B. Chellakkan Selvanesan +24
    bioRxivPreprintAll rights reservedFull textOncologybioRxiv
  4. Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results
    Robert C G Martin II, Rebekah Ruth White, Malcolm M Bilimoria +9
    The OncologistPeer-reviewedCC BY 4.0Full textOncologyPMC
  5. Coordinated upregulation of Hippo, NF-κB and interferon pathway genes in pancreatic ductal adenocarcinoma: a retrospective tissue qRT-PCR profiling study with external tumour-versus-non-tumour validation, molecular subtype and survival analyses.
    Eda Balkan, Murat Kızılkaya, Sevilay Özmen +5
    BMC gastroenterologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{glavcic2026oti1h1defined,
  title = {{OTI1H1-Defined MAGEA3-Directed Immunoreactivity and Survival in Pancreatic Ductal Adenocarcinoma: A Single-Center Study}},
  author = {Goran Glavčić and Marin Glavčić and Suzana Janković and Dubravka Mužina and Zdenko Bilić and Nina Blažević and Zvonimir Misir and Jasmina Hranjec and Andro Košec and Petra Radulović},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15218276},
  url = {https://www.mdpi.com/2077-0383/15/21/8276},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - OTI1H1-Defined MAGEA3-Directed Immunoreactivity and Survival in Pancreatic Ductal Adenocarcinoma: A Single-Center Study
AU  - Goran Glavčić
AU  - Marin Glavčić
AU  - Suzana Janković
AU  - Dubravka Mužina
AU  - Zdenko Bilić
AU  - Nina Blažević
AU  - Zvonimir Misir
AU  - Jasmina Hranjec
AU  - Andro Košec
AU  - Petra Radulović
PY  - 2026
DA  - 2026/10/24
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15218276
UR  - https://www.mdpi.com/2077-0383/15/21/8276
AB  - Background/Objectives: Melanoma-associated antigen A3 (MAGEA3) is a cancer–testis antigen with potential biological and prognostic relevance in pancreatic ductal adenocarcinoma (PDAC). This study evaluated the association between OTI1H1-defined MAGEA3-directed immunoreactivity and clinicopathological characteristics and overall survival after pancreatic resection for PDAC. Methods: This retrospective cohort included 76 patients with histologically confirmed PDAC. Patients who died within 30 postoperative days were excluded, and all tumors were retrospectively restaged according to the eighth edition of the AJCC TNM classification. Immunohistochemical staining was assessed using the mouse monoclonal anti-MAGE3 antibody clone OTI1H1 (ab140678, Abcam) by a single experienced pathologist blinded to clinical and outcome data. The percentage of immunoreactive tumor cells was retained as the principal exploratory quantitative measure; the prespecified <10% versus ≥10% classification was evaluated secondarily. Results: Thirty-six of 76 tumors (47.4%) had ≥10% OTI1H1-reactive tumor cells. When staining was modeled continuously, the adjusted HR per 10-percentage-point increase was 0.969 (95% CI 0.898–1.046; p = 0.420). For the secondary binary classification, the adjusted HR for ≥10% versus <10% staining was 0.745 (95% CI 0.417–1.331; p = 0.320). No statistically clear association with overall survival was observed; however, the confidence intervals do not exclude potentially clinically relevant associations in either direction. Conclusions: No statistically clear association between OTI1H1-defined immunoreactivity and overall survival was observed in this cohort. Because OTI1H1 has known cross-reactivity with selected MAGE-A family proteins and no orthogonal molecular validation was performed, these findings should be interpreted as assay-specific and do not establish biological inactivity of MAGEA3 or related MAGE-A proteins.
SN  - 2077-0383
ER  -